Drag a card by its title · ⚙ to size, swap or remove

The company

Spero Therapeutics, Inc.

SPRO · Nasdaq

Health CareBiotechnologyNot moving yet

SPRO stood above a rising 150-day average in 26 of the last 52 weekly readings, and has been out of that trend for the last 18 weeks. It is 42.1% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 18
Industry in uptrend: 16% -15 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $1.0M
Officials’ trades on record: 0
Institutions holding: 58 (+11)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 26 of 52 weeks.

20 Apr – 19 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months8

Buyers · sellers0 · 2

Who	Did	Shares	Traded
Esther RajaveluOfficer	sold	25,240at $2.51	4 May 2026filed 6 May 2026
Timothy KeutzerChief Operating Officer	sold	18,652at $2.36	6 Feb 2026filed 9 Feb 2026
Esther RajaveluOfficer	sold	37,101at $2.36	6 Feb 2026filed 9 Feb 2026
Esther RajaveluOfficer	sold	50,816at $2.36	6 Feb 2026filed 9 Feb 2026
Timothy KeutzerChief Operating Officer	sold	3,471at $2.24	4 Feb 2026filed 5 Feb 2026
Timothy KeutzerChief Operating Officer	sold	24,224at $2.14	3 Feb 2026filed 5 Feb 2026
Esther RajaveluOfficer	sold	18,442at $2.20	2 Feb 2026filed 4 Feb 2026
Timothy KeutzerChief Operating Officer	sold	18,891at $2.20	2 Feb 2026filed 5 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders58+11 on the quarter

New · exited23 · 12

Reported value$46.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
GSK plcunchanged · filed 13 Aug 2026	9,190,606$20.3M	00.0%
Pfizer Incunchanged · filed 13 Aug 2026	2,362,348$5.3M	00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	2,036,226$4.5M	+236,346+13.1%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026	947,904$2.1M	-241,331−20.3%
Alphabet Inc.unchanged · filed 7 Aug 2026	889,979$2.0M	00.0%
SUSQUEHANNA INTERNATIONAL GROUP, LLPadded · filed 14 Aug 2026	759,290$1.7M	+426,175+127.9%
BlackRock, Inc.added · filed 7 Aug 2026	594,404$1.3M	+161,202+37.2%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	566,329$1.3M	+46,407+8.9%
RAYMOND JAMES FINANCIAL INCnew · filed 14 Aug 2026	521,705$1.2M	+521,705
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 2026	382,814$846K	-502,817−56.8%